RecruitingNCT06726590
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
The Texas Interprofessional Pharmacogenomics Registry and Repository
Sponsor
Texas A&M University
Enrollment
3,000 participants
Start Date
Nov 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This program collects genetic and health information to help doctors choose the right medications for patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study builds a registry of patients who undergo pharmacogenomics (PGx) testing — genetic testing that predicts how your body processes medications — to understand how this testing influences prescribing decisions and patient outcomes.
**You may be eligible if...**
- Are eligible for pharmacogenomics (PGx) testing or PGx-guided care
- Take 5 or more medications (including over-the-counter drugs, supplements, cannabis, or other recreational substances)
- Able to provide consent to participate
**You may NOT be eligible if...**
- Are not eligible for PGx testing based on clinical assessment
- Take fewer than 5 medications
- Are unwilling to have genetic testing results stored in the registry
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06726590
Related Trials
A Natural History Study of Metabolic Sizing in Health and Disease
NCT053987831 location
Upstroke Time Measured by Photoplethysmography
NCT057955822 locations
Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer
NCT007606561 location
Childhood Cancer Survivor Study
NCT0112035331 locations
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
NCT0384764912 locations